CeriBell, Inc. (NASDAQ:CBLL) Receives Consensus Rating of “Moderate Buy” from Analysts

Shares of CeriBell, Inc. (NASDAQ:CBLL) have received an average recommendation of “Moderate Buy” from the six research firms that are covering the stock, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, four have assigned a buy recommendation and one has given a strong buy recommendation to the company. The average 1-year price target among brokerages that have updated their coverage on the stock in the last year is $22.20.

A number of research firms have recently issued reports on CBLL. Weiss Ratings upgraded CeriBell from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Monday, June 29th. Canaccord Genuity Group decreased their price target on CeriBell from $28.00 to $25.00 and set a “buy” rating for the company in a report on Tuesday, May 12th.

Insider Buying and Selling at CeriBell

In related news, major shareholder Tpg Gp A, Llc sold 202,368 shares of CeriBell stock in a transaction on Friday, June 26th. The shares were sold at an average price of $20.12, for a total transaction of $4,071,644.16. Following the sale, the insider owned 3,765,054 shares of the company’s stock, valued at $75,752,886.48. The trade was a 5.10% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CTO Raymond Woo sold 11,104 shares of the business’s stock in a transaction on Friday, May 1st. The stock was sold at an average price of $20.44, for a total transaction of $226,965.76. Following the completion of the transaction, the chief technology officer owned 197,648 shares in the company, valued at $4,039,925.12. This represents a 5.32% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders sold 350,789 shares of company stock valued at $6,946,191. 20.10% of the stock is owned by company insiders.

Institutional Trading of CeriBell

Hedge funds and other institutional investors have recently modified their holdings of the business. Strs Ohio bought a new stake in shares of CeriBell in the first quarter worth $27,000. Caitong International Asset Management Co. Ltd boosted its stake in CeriBell by 3,971.0% during the 4th quarter. Caitong International Asset Management Co. Ltd now owns 1,262 shares of the company’s stock valued at $28,000 after acquiring an additional 1,231 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank acquired a new position in CeriBell during the 3rd quarter worth $33,000. CWM LLC increased its position in shares of CeriBell by 1,178.5% in the 4th quarter. CWM LLC now owns 1,841 shares of the company’s stock worth $40,000 after purchasing an additional 1,697 shares during the last quarter. Finally, Tower Research Capital LLC TRC increased its position in shares of CeriBell by 353.8% in the 2nd quarter. Tower Research Capital LLC TRC now owns 2,310 shares of the company’s stock worth $43,000 after purchasing an additional 1,801 shares during the last quarter.

CeriBell Stock Performance

Shares of CBLL stock opened at $19.64 on Friday. The company has a current ratio of 10.44, a quick ratio of 10.01 and a debt-to-equity ratio of 0.14. The company has a market cap of $745.14 million, a PE ratio of -12.05 and a beta of 0.77. The company’s fifty day simple moving average is $18.67 and its 200-day simple moving average is $19.65. CeriBell has a 52 week low of $10.85 and a 52 week high of $24.33.

CeriBell (NASDAQ:CBLL) last announced its quarterly earnings results on Monday, May 11th. The company reported ($0.52) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.39) by ($0.13). The company had revenue of $26.49 million during the quarter, compared to analyst estimates of $26.09 million. CeriBell had a negative net margin of 63.51% and a negative return on equity of 38.19%. As a group, equities research analysts anticipate that CeriBell will post -1.69 EPS for the current year.

CeriBell Company Profile

CeriBell Corp (NASDAQ: CBLL) is a healthcare technology company specializing in the design, manufacture and sale of automated newborn hearing screening devices. The company offers a suite of medical diagnostic tools based on otoacoustic emissions (OAE) and auditory brainstem response (ABR) technologies, enabling early detection of auditory impairments in infants. CeriBell’s solutions are used in hospitals, birthing centers and audiology clinics to support universal newborn hearing screening programs aimed at improving language development outcomes through prompt intervention.

The company’s product portfolio includes handheld and desktop screening units, proprietary software for data management, and accessories designed to streamline testing workflows.